Highlights Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
4.74 ^USD	-1.86%		+0.42%	-7.78%

Apr. 25	Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	CI
Apr. 01	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	Apr. 25	CI
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01	CI
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	Feb. 13	MT
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	Dec. 27	MT
Vistagen	Dec. 27	MT
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27	CI
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $277.7M	Nov. 09	MT
Global markets live: Rio Tinto, Bank of America, J&J, Pfizer, Microsoft...	23-10-17
Vistagen Therapeutics, Inc. Provides Details Regarding Development Plans for Fasedienol	23-10-02	CI
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder	23-09-12	CI
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-05	CI
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol Nasal Spray in Social Anxiety Disorder	23-08-10	CI
Earnings Flash (VTGN) VISTAGEN Reports Q1 Revenue $177,600	23-08-10	MT
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol Nasal Spray in Social Anxiety Disorder	23-08-07	CI
Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats	23-07-18	CI
Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain	23-07-17	CI
VistaGen Gets Canadian Notice of Allowance for Patent Linked to Use of AV-101 for Dyskinesia	23-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Highlights

Filters